Akero Therapeutics, Inc. Akero Therapeutics, Inc.

Akero Therapeutics, Inc.

AKRO

Rankning i aktier #3722
Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing... Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing cardio-metabolic disorders, with a specific focus on nonalcoholic steatohepatitis (NASH). Its primary objective is the creation of therapeutic agents aimed at re-establishing metabolic equilibrium and enhancing overall well-being. The company's flagship investigational drug is efruxifermin (EFX), a synthetic analog of fibroblast growth factor 21. EFX is designed to shield cells from stress and modulate the systemic metabolism of fats, carbohydrates, and proteins throughout the body. This promising compound is currently undergoing evaluation in a Phase 2a clinical investigation, known as the BALANCED study, for individuals diagnosed with biopsy-confirmed NASH. Originally established as Pippin Pharmaceuticals, Inc., the organization rebranded as Akero Therapeutics, Inc. in May 2018. Founded in 2017, Akero Therapeutics maintains its corporate headquarters in South San Francisco, California.
Aktiekurs
$54.65
Senast synkroniserad: 2025-12-09
Marknadsvärde
$4.50B
Förändring (1 dag)
0.00%
Förändring (1 år)
1.50%
Land
US
Handel Akero Therapeutics, Inc. (AKRO)

Kategori

Healthcare
EPS för Akero Therapeutics, Inc. (AKRO)
EPS per September 2025 TTM: $-3.74
Enligt Akero Therapeutics, Inc.s senaste finansiella rapporter och aktiekurs är bolagets nuvarande EPS (TTM) $-3.74. Vid slutet av 2023 hade bolaget ett EPS på $-2.89, en ökning jämfört med EPS från 2022 som var $-2.87.
EPS-historik för Akero Therapeutics, Inc. från 2017 till 2026
EPS vid slutet av varje år
År EPS Ändra
2026 (TTM) $-3.74 -0.27%
2024 $-3.75 29.76%
2023 $-2.89 0.70%
2022 $-2.87 -0.69%
2021 $-2.89 14.68%
2020 $-2.52 -13.10%
2019 $-2.90 -24.68%
2018 $-3.85 2,306.25%
2017 $-0.16 0.00%
EPS för liknande företag eller konkurrenter
Företag EPS EPS-differens Land
$17.32 -563.10%
US
$-7.98 113.37%
US
$-5.29 41.44%
AU
- -
CH
$27.74 -841.71%
NL